Linked Life Data

15264996

Source:http://linkedlifedata.com/resource/pubmed/id/15264996

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2004-7-21
pubmed:abstractText
Chronic-obstructive pulmonary disease (COPD) is a global public health problem and its impact is increasing. Although only smoking cessation has been shown to alter the natural history of the disease, current treatment guidelines recommend the use of inhaled bronchodilators to decrease symptoms, improve lung function and quality of life and to prevent exacerbations. For a subset of patients with more severe disease, inhaled corticosteroids may also have a role in achieving these goals. Fluticasone propionate/salmeterol (Advair) or Seretide), GlaxoSmithKline) is a combination inhaled steroid and long-acting bronchodilator that is delivered by a dry-powder inhaler and was recently approved for use in COPD in the US. Fluticasone propionate/salmeterol is a potent bronchodilator and also appears to have important effects on the frequency of exacerbations and overall quality of life for some patients with COPD. Issues of patient selection as well as the pharmacology, efficacy and safety of the drug are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1744-7666
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1815-26
pubmed:dateRevised
2010-12-2
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.
pubmed:affiliation
Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, 215 THT, 1900 University Blvd, Birmingham, AL 35294, USA. mdransfield99@msn.com
pubmed:publicationType
Journal Article, Review